Digital Therapeutics Reimbursement in the U.S. (2025): How to Win Now

Medicare Digital Mental Health Treatment (DMHT) Codes 2025 Explained

Medicare has officially opened the door to reimbursable digital therapeutics. In 2025, CMS introduced three new HCPCS codes—G0552, G0553, and G0554—under the Digital Mental Health Treatment (DMHT) programme, creating a paid, clinician-supervised pathway for software-delivered treatment and ongoing management.

Unlike Remote Therapeutic Monitoring (RTM), the DMHT codes are designed for regulated, FDA-cleared digital mental health “devices” used within prescriber-managed behavioural health plans. These codes reward genuine therapeutic engagement, not passive monitoring and mark the first step toward a comprehensive Medicare digital therapeutics framework.

Early Utilisation: Small Numbers, Big Signal

Early 2025 data show modest but real uptake of DMHT billing across behavioural health clinics. CMS views this as the expected Phase-I adoption curve, enabling it to evaluate documentation standards, provider readiness, and patient outcomes before broader expansion.

Each claim tells CMS that digital therapeutics are ready for real-world reimbursement and that clinicians are willing to integrate validated software into care pathways. Expect incremental rule refinements and spill over into adjacent therapeutic areas, including chronic disease management.

The “Big Bang” Ahead: PDTx and Algorithm-Based Services

Two major federal bills could redefine digital therapeutics reimbursement far beyond mental health:

- Access to Prescription Digital Therapeutics (PDTx) Act (S.1702 / H.R.3288): Would create a statutory benefit category for Prescription Digital Therapeutics, embedding coverage, payment, and HCPCS issuance directly into the Social Security Act.

- Health Tech Investment Act (S.1399): Would authorise a Medicare payment pathway for algorithm-based healthcare services, covering software subscriptions, infrastructure costs, and AI-enabled interventions through OPPS/APC mechanics and a “new-technology” payment window.

Together, these bills would normalise reimbursement for digital therapeutics across all disease areas—not just behavioural health.

What Wins in 2025

Right now, success under Medicare DMHT depends on mastering four fundamentals:

1. Prescriber-managed behavioural plans with documented clinical oversight.

1. FDA clearance or De Novo classification confirming DMHT “device” status.

1. Measured, validated clinical outcomes tied to recognised therapeutic endpoints.

1. Fluent revenue-cycle management using G-codes G0552–G0554—including time increments, incident-to supervision, and claim documentation.

When those pillars are in place, digital mental health innovators can bill compliantly, prove value, and scale reimbursement under Medicare.

The Bottom Line

Odelle Technology helps digital therapeutics companies get reimbursed.
From Medicare DMHT codes (G0552–G0554) to emerging PDTx and AI reimbursement frameworks, Odelle bridges evidence, policy, and payment, turning innovation into access.

1) Understanding Medicare Digital Mental Health Treatment (DMHT) Codes 2025 — G0552, G0553, G0554

The Medicare Digital Mental Health Treatment (DMHT) codes G0552, G0553, and G0554 represent a major milestone in reimbursable digital therapeutics and behavioural health treatment under Medicare in 2025. These new HCPCS Level II codes allow clinicians to bill for FDA-regulated digital mental health devices and software that deliver clinician-supervised, evidence-based treatment as part of an ongoing behavioural health plan.

What DMHT Codes Cover

Each code is time-based and designed to reflect active, therapeutic management rather than passive monitoring:

- G0552 — Initial 20 minutes of clinical time managing a digital mental health treatment.

- G0553 — Add-on code for each additional 20 minutes.

- G0554 — Extended management for complex or multi-condition patients.

To qualify for reimbursement, providers must document therapeutic interaction, clinical decision-making, and integration with the patient’s behavioural treatment plan. Proper documentation and supervision are essential to avoid denials.

Why DMHT Codes Matter in 2025

The new DMHT reimbursement framework closes a long-standing policy gap between Remote Therapeutic Monitoring (RTM) and psychotherapy codes, establishing a formal Medicare payment pathway for software-delivered treatment. By recognising digital therapeutics as true clinical interventions, CMS has effectively validated this emerging field within the traditional fee-for-service environment.

Implementation and Workflow Integration

For clinicians, digital health leaders, and RCM managers, DMHT success depends on seamless workflow integration:

- Confirm the digital tool has FDA clearance or De Novo classification and qualifies as a “device” under CMS rules.

- Embed DMHT into prescriber-managed treatment plans with real-time supervision.

- Map billing systems to G0552–G0554 increments and ensure accurate time tracking.

- Train clinical staff on documentation and compliance requirements.

Expert Insight and Practical Guidance

For those seeking a concise operational overview, Xealth’s DMHT explainer remains a highly referenced guide. It clearly illustrates who can prescribe, where DMHT fits within behavioural-health workflows, and how it differs from RTM. For board presentations, it provides a two-minute snapshot of how Medicare digital mental health billing functions in practice.

2) Understanding Medicare Digital Mental Health Treatment (DMHT) Codes 2025 — G0552 to G0554

The Medicare Digital Mental Health Treatment (DMHT) codes—G0552, G0553, and G0554—form the foundation of reimbursement for clinician-supervised digital mental health care in 2025. These new HCPCS codes enable payment for FDA-regulated digital therapeutics and software-based behavioural treatments delivered under a prescriber-managed plan of care.

In practice, DMHT billing is built around approved “devices” (i.e. regulated software-as-a-medical-device) combined with monthly, time-based treatment-management services:

- G0552 covers the first 20 minutes of clinician time spent managing digital treatment.

- G0553 and G0554 serve as add-on codes for each additional 20-minute increment.

- Documentation must clearly show therapeutic interaction, patient progress, and integration with the behavioural treatment plan to avoid denials or audit risks.

For operational teams, these codes bridge the gap between traditional psychotherapy and digital behavioural health interventions, allowing clinicians to deliver hybrid care models where evidence-based software complements in-person sessions.

Workflow and Prescriber Guidance

For those managing digital behavioural workflows, Xealth’s DMHT explainer remains one of the most concise, practical resources available. It outlines:

- Who can prescribe DMHT services (psychiatrists, psychologists, clinical social workers, NPs, and PAs).

- Where DMHT fits into existing behavioural health workflows, particularly alongside Remote Therapeutic Monitoring (RTM) codes.

- How to align documentation and supervision requirements to meet CMS billing standards.

For presentations or board decks, it’s arguably the clearest two-minute narrative explaining how Medicare digital mental health reimbursement actually works.

3) Early utilisation: signal, not noise

Early 2025 reporting shows modest but measurable use of DMHT codes—exactly the pattern CMS expects while it assesses behaviour, documentation quality, and patient mix. Treat this as “Phase I adoption”: enough claims to keep policy momentum, not enough to test capacity limits. Early 2025 Medicare data show modest but measurable utilisation of the new Digital Mental Health Treatment (DMHT) codes, a sign that the system is functioning exactly as intended. These early claims form the foundation of Phase I adoption a deliberate, observation-heavy stage where CMS monitors how clinicians, payers, and patients interact with digital mental health services.

The numbers may appear small, but they are a signal rather than noise. CMS historically prefers a gradual ramp-up when introducing new benefit categories, focusing first on documentation quality, billing consistency, and clinical appropriateness. In this context, limited uptake isn’t failure—it’s validation that the infrastructure for reimbursable digital mental health treatment is being established in a controlled, data-driven manner.

This measured utilisation phase helps CMS and stakeholders:

- Track real-world workflow integration between software-delivered treatment and traditional psychotherapy.

- Identify the patient populations most likely to benefit (e.g., anxiety, depression, PTSD).

- Assess provider readiness and documentation accuracy under the new HCPCS G-codes.

- Establish baseline data for cost-effectiveness and outcome benchmarking, paving the way for potential expansion into other digital therapeutic categories.

As adoption scales, expect to see the DMHT framework evolve—first through refinements in billing guidance, then possibly through broader legislative or CMS rulemaking that formalises a Prescription Digital Therapeutics (PDTx) benefit category. For innovators, this period offers a unique opportunity to build evidence, refine compliance workflows, and position early clinical users as thought leaders in digital mental health reimbursement. do follow https://www.linkedin.com/company/odelle-technology

4) Beyond DMHT: From Medicare Digital Mental Health Treatment to Prescription Digital Therapeutics (PDTx)

While the Digital Mental Health Treatment (DMHT) codes mark a major step forward for reimbursable digital care, two federal legislative proposals could take the next leap—transforming digital therapeutics from a behavioural-health carve-out into a core Medicare benefit category.

Access to Prescription Digital Therapeutics Act (S.1702 / H.R.3288)

This bipartisan bill would formally define “Prescription Digital Therapeutics (PDTx)” within the Social Security Act, mandating that Medicare and Medicaid establish coverage and payment mechanisms for clinically validated digital treatments. Crucially, it directs CMS to:

- Create HCPCS coding and payment timelines specific to PDTx products.

- Apply consistent benefit-category classification, similar to drugs or devices.

- Ensure access equity for patients across public insurance programmes.

In short, the bill would move digital therapeutics from ad-hoc coverage to a statutory reimbursement framework—a landmark change comparable to how telehealth entered the Medicare rulebook two decades ago.

Health Tech Investment Act (S.1399)

Running in parallel, the Health Tech Investment Act would establish a Medicare payment pathway for algorithm-based and AI-enabled healthcare services. It recognises the infrastructure and subscription costs behind software-as-a-medical-device (SaMD) and decision-support systems, allowing reimbursement through:

- The Outpatient Prospective Payment System (OPPS) and Ambulatory Payment Classifications (APCs).

- A protected “new-technology period” that supports early adoption before long-term rate setting.

This mechanism creates a viable reimbursement lane for AI, digital therapeutics, and data-driven clinical platforms a pivotal development for companies building digital endpoints and remote-care algorithms.

Industry Momentum and Stakeholder Support

Signals from key stakeholders—especially AdvaMed®, which has publicly endorsed both legislative efforts—reflect strong industry alignment around codifying payment pathways for digital therapeutics beyond mental health.
The emerging consensus is clear: to sustain innovation in digital medicine, CMS must evolve from temporary DMHT codes to a dedicated Prescription Digital Therapeutics benefit, recognising software-delivered therapy as true clinical care.

5) Evidence standards that convert Sceptics

What payers are scanning for now: do follow https://www.linkedin.com/company/odelle-technology/?viewAsMember=true

Evidence Standards That Convert Sceptics

As the Medicare Digital Mental Health Treatment (DMHT) codes mature, CMS and commercial payers are closely evaluating which digital therapeutics truly qualify as clinician-supervised treatment, not just engagement tools or passive monitoring apps. To meet emerging reimbursement expectations, innovators must build evidence aligned with regulatory, clinical, and economic benchmarks that stand up to audit and HTA review.

1. Regulatory Clarity

Ensure your product fits a clear FDA regulatory pathway—ideally with 510(k) clearance, De Novo classification, or Breakthrough Device designation that supports its status as a DMHT-eligible medical device. Payers increasingly prioritise FDA-cleared software-as-a-medical-device (SaMD) solutions over wellness or self-help apps when determining reimbursement eligibility.

2. Clinically Validated Outcomes

Evidence must demonstrate measurable clinical improvement tied to guideline-relevant endpoints—for example, reductions in PHQ-9 or GAD-7 scores for depression and anxiety, sustained symptom remission, or validated quality-of-life metrics. Engagement data alone no longer suffice; CMS reviewers are looking for therapeutic efficacy comparable to in-person care.

3. Treatment-Plan Integration and Oversight

To pass compliance review, digital mental health solutions must show structured integration within physician-supervised treatment plans. That means:

- Clear documentation of prescriber oversight and patient consent

- Defined data flows between EHRs, therapists, and care managers

- Audit-ready logs that align with CMS documentation and time-tracking standards

This transforms a digital platform from a passive tracker into an active therapeutic intervention—exactly what CMS outlined in its final DMHT rule.

4. Economic Signal and Real-World Value

Ultimately, CMS and private insurers want proof of economic value. Early data that show reduced acute utilisation, lower hospitalisations, fewer escalations, and improved adherence build a strong case for continued payment. Pairing outcomes with budget-impact or cost-utility analysis can further demonstrate alignment with Medicare’s value-based reimbursement framework.

6) How to Get Paid Under Medicare Digital Mental Health Treatment (DMHT) Codes in 2025–2026

Navigating Medicare’s new Digital Mental Health Treatment (DMHT) codes is no longer theoretical—2025 is the year real reimbursement begins. For digital therapeutics developers, clinicians, and RCM teams, the challenge is turning policy clarity into payment reality.

Below are the two critical lanes that determine success: the DMHT implementation lane (operational execution) and the policy evolution lane (strategic positioning for future benefit categories).

🔹 Now: The DMHT Implementation Lane

To secure and sustain payment under HCPCS G0552–G0554, your product and workflows must align tightly with CMS’s digital-treatment criteria.

1. Confirm Regulatory Fit
Ensure your product qualifies as a regulated medical device under FDA SaMD or Class II/III rules, and that it is prescribed or managed under a clinician-supervised treatment plan. CMS explicitly ties DMHT reimbursement to provider oversight—not standalone self-help apps.

2. Build a Bulletproof Revenue Cycle Management (RCM) Process
Create a compliant billing infrastructure that maps to G0552–G0554 time increments and incident-to supervision requirements.

- Train clinics and mental-health providers on documentation, supervision, and claim submission.

- Develop payer education materials that explain how your digital therapeutic delivers measurable treatment, not passive monitoring.

- Use RCM analytics to flag incomplete documentation and ensure audit-proof compliance.

3. Instrument Outcomes Like a Mini-HTA
Every quarter, capture and report outcomes as if producing a mini health-technology assessment (HTA)—because you are.
Measure:

- Clinical effectiveness (validated symptom scales such as PHQ-9, GAD-7)

- Adherence and engagement metrics

- Cost offsets such as reduced hospitalisations, ED visits, and crisis escalations

These data not only sustain reimbursement but also prepare you for the next stage: Prescription Digital Therapeutics (PDTx) integration.

🔹 Next: The Policy and PDTx Evolution Lane

CMS’s current DMHT framework is just the start. Two major bills—the Access to Prescription Digital Therapeutics Act (S.1702 / H.R.3288) and the Health Tech Investment Act (S.1399)—are shaping the long-term reimbursement ecosystem for digital health and AI-driven therapeutics.

1. Track and Prepare for Legislative Pathways
Stay current on both bills and prepare concise internal briefs showing how your product would align:

- S.1702 / H.R.3288: Creates a Prescription Digital Therapeutics (PDTx) statutory benefit category under the Social Security Act.

- S.1399: Establishes a payment pathway for algorithm-based and AI-enabled health services through OPPS/APC mechanisms with a protected “new-technology” period.

2. Build PDTx-Ready Dossiers Now
If your solution extends beyond mental health—into chronic conditions such as diabetes, COPD, pain, or insomnia—begin developing PDTx-ready evidence dossiers. Include:

- Longitudinal outcomes data

- Cost-utility and budget-impact models

- Real-world evidence (RWE) supporting clinical effectiveness

Position your product so that, when CMS formalises a PDTx reimbursement category, you can be first in line.

7) Key FAQs

Q1. Are DMHT codes the same as RTM?
No. DMHT codes pay for treatment (and monthly treatment-management) for digital mental health devices used under a behavioural plan; RTM is a different construct focused on monitoring. CMS explicitly created a separate DMHT lane in the 2025 PFS final rule. cms.gov+1

Q2. Which HCPCS codes apply?
G0552–G0554 (with time increments and incident-to requirements). Verify descriptors and documentation to avoid denials.

Q3. Is Medicare coverage “broad” for all DTx now?
Not yet. Today’s coverage is scoped to DMHT. Broader PDTx coverage requires new statute/regulatory expansion; the Access to PDTx Act would create that benefit category.

Q4. What’s the adoption signal so far?
Early, measurable use (Q1/Q2 2025) with CMS and media tracking impact; expect iterative policy adjustments.

Q5. What should I read to brief my exec team fast?
CMS fact sheet/final rule summary; APA/AAPC practicals; Xealth for provider ops; Healthcare Brew for market pulse.

- Understanding Medicare Digital Mental Health Treatment (DMHT) Codes 2025 is critical for digital therapeutics teams…”

- “The introduction of DMHT codes 2025 redefines how software-based treatments are reimbursed.”

- “To qualify under Medicare’s DMHT codes, your digital mental health device must…”

References for “Medicare Digital Mental Health Treatment (DMHT) Codes 2025”

1. Centers for Medicare & Medicaid Services (CMS).
  CY 2025 Medicare Physician Fee Schedule Final Rule: Payment Policies under the Physician Fee Schedule and Other Revisions to Part B.
  https://www.cms.gov/files/document/mm13887-medicare-physician-fee-schedule-final-rule-summary-cy-2025.pdf

1. Centers for Medicare & Medicaid Services (CMS).
  Behavioral Health Integration Services (MLN909432).
  https://www.cms.gov/files/document/mln909432-behavioral-health-integration-services.pdf

1. AAPC (American Academy of Professional Coders).
  Medicare Implements Digital Mental Health Treatment Codes.
  https://www.aapc.com/blog/93026-medicare-implements-digital-mental-health-treatment-codes

1. APA Services (American Psychological Association).
  2025 Medicare Changes for Psychologists and Behavioural Health Providers.
  https://www.apaservices.org/practice/reimbursement/government/2025-medicare-changes

1. Xealth.
  CMS Will Start Paying for Digital Therapeutics (DTx).
  https://www.xealth.com/blog/cms-will-start-paying-for-dtx

1. Congress.gov.
  S.1702 — Access to Prescription Digital Therapeutics Act of 2023.
  https://www.congress.gov/bill/118th-congress/senate-bill/1702

1. Congress.gov.
  S.1399 — Health Tech Investment Act of 2023.
  https://www.congress.gov/bill/118th-congress/senate-bill/1399

1. AdvaMed.
  Statement on the Access to Prescription Digital Therapeutics Act (S.1702/H.R.3288).
  https://www.advamed.org/advamed-response-to-access-to-prescription-digital-therapeutics-act

1. Federal Register.
  Medicare Program: Revisions to Payment Policies under the Physician Fee Schedule, CY 2025.
  https://www.federalregister.gov/documents/2024/11/15/2024-25972/medicare-program-revisions-to-payment-policies-under-the-physician-fee-schedule-cy-2025

1. Healthcare Brew.
  CMS Adds New Codes for Digital Mental Health Treatment in 2025.
  https://www.healthcare-brew.com/stories/2025/01/05/cms-adds-digital-mental-health-treatment-codes

Bibliography — Medicare Digital Mental Health Treatment (DMHT) Codes 2025

Centers for Medicare & Medicaid Services (CMS). (2024). CY 2025 Medicare Physician Fee Schedule Final Rule: Digital Mental Health Treatment Codes G0552–G0554. CMS, U.S. Department of Health & Human Services. Available at cms.gov.
Defines the creation of Medicare Digital Mental Health Treatment (DMHT) codes, clarifies professional supervision, and establishes reimbursement for software-delivered therapy.

Centers for Medicare & Medicaid Services (CMS). (2024). Behavioural Health Integration Services MLN909432. CMS Learning Network Publication.
Provides operational context for integrating DMHT billing within behavioural health and chronic care management frameworks.

American Academy of Professional Coders (AAPC). (2025). Medicare Implements Digital Mental Health Treatment Codes G0552–G0554.
Outlines HCPCS descriptors, 20-minute time increments, and “incident-to” documentation standards essential for compliant DMHT reimbursement.

American Psychological Association (APA Services). (2025). Medicare 2025 Updates for Psychologists and Behavioural Health Providers.
Explains clinical supervision and documentation expectations under the new Medicare Digital Mental Health Treatment (DMHT) reimbursement policy.

Xealth. (2025). CMS Will Start Paying for Digital Therapeutics (DTx) under DMHT Codes.
Illustrates provider workflow integration, EHR alignment, and revenue-cycle adaptation for DMHT reimbursement in real clinical settings.

Healthcare Brew. (2025). CMS Adds New Codes for Digital Mental Health Treatment in 2025.
Reports early utilisation trends and adoption data for DMHT codes, confirming real-world Medicare claims activity.

Congress.gov. (2023). Access to Prescription Digital Therapeutics Act (S. 1702 / H.R. 3288).
Introduces a statutory benefit category for Prescription Digital Therapeutics (PDTx) within Medicare and Medicaid, expanding beyond behavioural health.

Congress.gov. (2023). Health Tech Investment Act (S. 1399).
Proposes a payment pathway for algorithm-based digital health and AI-driven clinical decision-support services under Medicare’s OPPS/APC structures.

AdvaMed – Advanced Medical Technology Association. (2024). AdvaMed Statement on the Access to Prescription Digital Therapeutics Act.
Demonstrates strong industry support for establishing permanent Medicare reimbursement for PDTx, confirming stakeholder alignment.

Federal Register. (2024). Medicare Program: Revisions to Payment Policies under the Physician Fee Schedule, CY 2025.
Provides the official regulatory text defining how Digital Mental Health Treatment (DMHT) codes are implemented and monitored for compliance.

@AI #aicommunity #digitalmarketing #googledevelopers #intellectualproperty ~#emmanuelmacron